A detailed history of Savant Capital, LLC transactions in Novo Nordisk A S stock. As of the latest transaction made, Savant Capital, LLC holds 12,319 shares of NVO stock, worth $1.29 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
12,319
Previous 12,587 2.13%
Holding current value
$1.29 Million
Previous $1.8 Million 18.37%
% of portfolio
0.01%
Previous 0.02%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 04, 2024

SELL
$119.07 - $145.42 $31,910 - $38,972
-268 Reduced 2.13%
12,319 $1.47 Million
Q2 2024

Aug 05, 2024

BUY
$122.71 - $146.91 $214,865 - $257,239
1,751 Added 16.16%
12,587 $1.8 Million
Q1 2024

May 03, 2024

BUY
$102.11 - $135.92 $51,769 - $68,911
507 Added 4.91%
10,836 $1.39 Million
Q4 2023

Feb 05, 2024

SELL
$87.78 - $105.45 $22,032 - $26,467
-251 Reduced 2.37%
10,329 $1.07 Million
Q3 2023

Nov 06, 2023

BUY
$90.94 - $199.54 $504,080 - $1.11 Million
5,543 Added 110.05%
10,580 $962,000
Q2 2023

Aug 04, 2023

BUY
$155.98 - $172.65 $22,929 - $25,379
147 Added 3.01%
5,037 $815,000
Q1 2023

May 02, 2023

BUY
$132.34 - $159.14 $36,393 - $43,763
275 Added 5.96%
4,890 $778,000
Q4 2022

Feb 06, 2023

BUY
$102.55 - $135.33 $109,831 - $144,938
1,071 Added 30.22%
4,615 $624,000
Q3 2022

Oct 28, 2022

SELL
$95.28 - $116.93 $20,104 - $24,672
-211 Reduced 5.62%
3,544 $353,000
Q2 2022

Jul 22, 2022

SELL
$103.24 - $121.81 $12,595 - $14,860
-122 Reduced 3.15%
3,755 $418,000
Q1 2022

May 05, 2022

SELL
$93.1 - $112.54 $22,623 - $27,347
-243 Reduced 5.9%
3,877 $431,000
Q4 2021

Feb 08, 2022

BUY
$95.88 - $117.08 $395,025 - $482,369
4,120 New
4,120 $461,000

Others Institutions Holding NVO

About NOVO NORDISK A S


  • Ticker NVO
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 2,257,289,984
  • Market Cap $237B
  • Description
  • Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...
More about NVO
Track This Portfolio

Track Savant Capital, LLC Portfolio

Follow Savant Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Savant Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Savant Capital, LLC with notifications on news.